PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 2997-3004

  Logan, Joshua E ^a   Mostofizadeh, Nikayeh ^a   Desai, Amrita J ^a   Von Euw, Erika ^a   Conklin, Dylan ^a   Konkankit, Veerauo ^a   Hamidi, Habib ^a   Eckardt, Mark ^a   Anderson, Lee ^a   Chen, Hsiao Wang ^a   Ginther, Charles ^a   Taschereau, Eileen ^a   Bui, Peter H ^a   Christensen, James G ^b   Belldegrun, Arie S ^a   Slamon, Dennis J ^a   Kabbinavar, Fairooz F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CDKN2A; Cellcycle inhibition; E2F1; p16; Palbociclib; PD 0322991; Renal cell carcinoma

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; MOLECULAR MARKER; PALBOCICLIB; PROTEIN P15; PROTEIN P16; RUBIDIUM ION; TRANSCRIPTION FACTOR E2F1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CDKN2A; CELL-CYCLE INHIBITION; E2F1; P16; PALBOCICLIB; PD-0322991; RENAL CELL CARCINOMA;

APOPTOSIS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84883279733     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Stewart ZA, Westfall MD and Pietenpol JA: Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 24(3): 139-145, 2003.
2. Vidaurreta M, Maestro ML, Sanz-Casla MT, Maestro C, Rafael C, Veganzones S, Moreno J, Blanco J, Silmi A and Arroyo M: Inactivation of p16 by CpG hypermethylation in renal cell carcinoma. Urol Oncol 26(3): 239-245, 2008.
3. Harbour JW, Luo RX, Dei Santi A, Postigo AA and Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98(6): 859-869, 1999.
4. Johnson DG, Schwarz JK, Cress WD and Nevins JR: Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365(6444): 349-352, 1993.
5. Parry D, Mahony D, Wills K and Lees E: Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 19(3): 1775-1783, 1999.
6. Hanahan D and Weinberg RA: Hallmarks of Cancer: The Next Generation. Cell 144(5): 646-674, 2011.
7. Kohno T andYokota J: Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: deduction from structural analysis of breakpoints for deletions. DNA Repair 5(9-10): 1273-1281, 2006.
8. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter J, Buckler A, Gabrielson E, Tockman M, Cho K, Hedrick L, Bova G, Isaacs W, Koch W, Schwab D and Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11(2): 210-212, 1995.
9. Merlo A, Herman JG, Mao L, Lee D, Gabrielson E, Burger P, Baylin S and Sidransky D: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1(7): 686-692, 1995.
10. Liggett W and Sidransksy D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16(3): 1197-1206, 1998.
11. Sanz-Casla MT, Maestro ML, del Barco V, Zanna I, Moreno J, Vidauretta M, Almansa I, Fernandez C, Blanco J, Maestro C and Resel L: Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol Res 31(3): 159-162, 2003.
12. Kasahara T, Bilim V, Hara N, Takahashi K and Tomita Y: Homozygous deletions of the INK4a/ARF locus in renal cell cancer. Anticancer Res 26(6B): 4299-4305, 2006.
13. Hedberg Y, Ljungberg B, Roos G and Landberg G: Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins. Int J Cancer 109(2): 189-193, 2004.
14. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade MA, Trachet E, Albassam M, Zheng XX, Leopold WR, Pryer NK and Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3(11): 1427-1438, 2004.
15. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G and Slamon DJ: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11(5): R77, 2009.
16. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Courtney R and O'Dwyer PJ: Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104(12): 1862-1868, 2011.
17. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D and Vokes EE: Flavopiridol, a novel cyclindependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 18(2): 371-375, 2000.
18. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang H, Anderson L, Kalli K, Finn R, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ: Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer. Clin Cancer Res 17(6): 1591-1602, 2011.
19. Ikuerowo SO, Kuczyk MA, Wasielewski von R, Shittu OB, Jonas U, Machtens S and Serth J: p16INK4a expression and clinicopathologic parameters in renal cell carcinoma. Eur Urol 51(3): 732-737, 2007.
20. Sanjmyatav J, Junker K, Matthes S, Muehr M, Sava D, Sternal M, Wassendorf S, Kreuz M, Gajda M, Wunderlich H and Schwaenen C: Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma. J Urol 186(5): 2078-2083, 2011.
21. Brunelli M, Eccher A, Gobbo S, Ficarra V, Novara G, Cossu- Rocca P, Bonettti F, Menestrina F, Cheng L, Eble JN and Martignoni G: Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 21(1): 1-6, 2008.
22. Klatte T, Rao PN, de Martino M, La Rochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS and Pantuck AJ: Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma. J Clin Oncol 27(5): 746-753, 2009.